Clinical value of ranibizumab combined with fundus laser in the treatment of macular edema secondary to branch retinal vein occlusion / 中国基层医药

Objective@#To investigate the clinical value of ranibizumab combined with fundus laser in the treatment of macular edema secondary to branch retinal vein occlusion(RVO).@*Methods@#From June 2016 to June 2017, 98 patients with RVO secondary macular edema in the People's Hospital of Linfen were randomly divided into three groups according to the digital table: A group (30 cases) treated with simple fundus laser, B group (33 cases) treated with intravitreal injection of ranibizumab, C group(35 cases) treated with fundus laser combined with intravitreal injection of ranibizumab.The best corrected visual acuity(BCVA), macular fovea thickness(CMT), leakage rate, injection times and complications were compared among the three groups before and after treatment.@*Results@#At 3, 6, 9, 12 months after treatment, the BCVA among A group, B group and C group had statistically significant differences (F=4.165, 5.021, 6.954, all P<0.05), and the BCVA of C group was better than that of B group, the BCVA of B group was better than that of A group (t=3.985, 3.852, 3.779, 4.021, 3.624, 3.729, all P<0.05). There were statistically significant differences in CMT among A group, B group and C group at 3 months and 6 months after treatment (F=6.772, 14.025, all P<0.05), and the CMT of C group was less than that of B group, the CMT of B group was less than that of A group (t=5.325, 11.251, 3.992, 6.895, all P<0.05). At 6 months after treatment, the leakage rate in C group (2.86%) was lower than that in B group (18.18%), the leakage rate in B group was lower than that in A group (23.33%) (χ2=6.148, P<0.05). The injection times of ranibizumab in B group was (2.93±1.52), which was significantly less than that in C group (2.00±0.56)(t=3.349, P<0.05).@*Conclusion@#The short-term clinical effect of ranibizumab combined with fundus laser in the treatment of macular edema secondary to RVO is better than laser therapy and ranibizumab alone, and the injection times of ranibizumab can be reduced.

Clinical value of ranibizumab combined with fundus laser in the treatment of macular edema secondary to branch retinal vein occlusion / 中国基层医药

Objective To investigate the clinical value of ranibizumab combined with fundus laser in the treatment of macular edema secondary to branch retinal vein occlusion (RVO).Methods From June 2016 to June 2017,98 patients with RVO secondary macular edema in the People's Hospital of Linfen were randomly divided into three groups according to the digital table:A group (30 cases) treated with simple fundus laser,B group (33 cases) treated with intravitreal injection of ranibizumab,C group(35 cases) treated with fundus laser combined with intravitreal injection of ranibizumab.The best corrected visual acuity (BCVA),macular fovea thickness (CMT),leakage rate,injection times and complications were compared among the three groups before and after treatment.Results At 3,6,9,12 months after treatment,the BCVA among A group,B group and C group had statistically significant differences (F=4.165,5.021,6.954,all P ＜0.05),and the BCVA of C group was better than that of B group,the BCVA of B group was better than that of A group (t =3.985,3.852,3.779,4.021,3.624,3.729,all P ＜0.05).There were statistically significant differences in CMT among A group,B group and C group at 3 months and 6 months after treatment (F =6.772,14.025,all P ＜ 0.05),and the CMT of C group was less than that of B group,the CMT of B group was less than that of A group (t =5.325,11.251,3.992,6.895,all P ＜ 0.05).At 6 months after treatment,the leakage rate in C group (2.86％) was lower than that in B group (18.18％),the leakage rate in B group was lower than that in A group (23.33％) (x2 =6.148,P ＜ 0.05).The injection times of ranibizumab in B group was (2.93 ± 1.52),which was significantly less than that in C group (2.00 ± 0.56) (t =3.349,P ＜ 0.05).Conclusion The short-term clinical effect of ranibizumab combined with fundus laser in the treatment of macular edema secondary to RVO is better than laser therapy and ranibizumab alone,and the injection times of ranibizumab can be reduced.

The changes of cellular immunity in 560 cases of hand-foot-mouth disease children / 中国医师杂志

Objective To investigate the relationship of cellular immunity of the hand-foot-mouth disease (HFMD) children and the disease severity and the variation following the recovery of disease.Methods A total of 560 HFMD cases was collected,and divided into severe and common groups.Another 120 cases were collected for comparison.T cell subsets (CD3 +,CD4 +,and CD8 +) rates were tested.The difference in cell immunity in each group were compared,and the comparison of cell immunity improv-ment during acute and recovery periods was conducted at the same time.Results In the 560 cases of children with HFMD,CoxA16-positive rate in common group was higher than that in severe group (x2 =280.72,P ＜0.01,severe cases); EV71 and other virus positive rates in severe group were higher than that in common group (x2 =127.75,P ＜ 0.01,x2 =5.43,P ＜ 0.05).Cell immunity was compared among3 groups (t =9.82,4.98,3.06); CD3+,CD4+,CD8+ results,tested within 2h after admission and after 1 week,were compared between severe and common groups (common group t =7.73,3.86,4.71; severe group t =6.13,2.60,3.36).Compared to severe group,cell immunity improvement was more obvious between before and after 1-week treatment in common group (t =2.57,2.51,2.95).The difference was statistically significant (P ＜ 0.05).Conclusions According to the etiology test of children with HFMD,CoxA16-positive rate was higher in common group; EV71 and other virus positive rates were higher in severe group.Cell immunity function decreased in severe and common group at the beginning of the disease; it was,however,significantly restored after 1-week treatment; and it was related to the severity of clinical symptoms.

Additive Antinociception between Intrathecal Sildenafil and Morphine in the Rat Formalin Test

The possible characteristics of spinal interaction between sildenafil (phosphodiesterase 5 inhibitor) and morphine on formalin-induced nociception in rats was examined. Then the role of the opioid receptor in the effect of sildenafil was further investigated. Catheters were inserted into the intrathecal space of male Sprague-Dawley rats. For induction of pain, 50 microliter of 5% formalin solution was applied to the hindpaw. Isobolographic analysis was used for the evaluation of drug interaction between sildenafil and morphine. Furthermore, naloxone was intrathecally given to verify the involvement of the opioid receptor in the antinociception of sildenafil. Both sildenafil and morphine produced an antinociceptive effect during phase 1 and phase 2 in the formalin test. The isobolographic analysis revealed an additive interaction after intrathecal delivery of the sildenafil-morphine mixture in both phases. Intrathecal naloxone reversed the antinociception of sildenafil in both phases. These results suggest that sildenafil, morphine, and the mixture of the two drugs are effective against acute pain and facilitated pain state at the spinal level. Thus, the spinal combination of sildenafil with morphine may be useful in the management of the same state. Furthermore, the opioid receptor is contributable to the antinocieptive mechanism of sildenafil at the spinal level.

Effect of Autologous or Allogeneic Anti-CD3 Monoclonal Antibody Activated Killer Cells on Normal Hematopoietic Cells / 中国实验血液学杂志

In order to investigate the effect of autologous and allogeneic anti-CD3 McAb activated killer cells (CD3AK) on normal hematopoietic cells, the immobilized anti-CD3 McAb and low concentration IL-2 were used to activate CD3AK. Flow cytometry was used to assay the phenotype change of CD3AK to analyze the proportional change of CD34(+) cells in normal bone marrow mononuclear cells (BMMNC) cocultured with autologous or allogeneic CD3AK. The effect of CD3AK on normal hematopoietic progenitor cells was also assayed by methylcellulose clonogenic culture of CFU-GM. It was found that 3 - 5 micro g/ml immobilized anti-CD3 McAb and 100 U/ml IL-2 could activate CD3AK effectively. There were 99.51% CD3(+) cells in CD3AK groups. When BMMNCs from healthy volunteers were cocultured with allogeneic CD3AK for six hours, the percentage of CD34(+) cells was decreased 32.37%. CD3AK had no significant influence on autologous BMMNC. Allogeneic and autologous CD3AK were cultured with BMMNC from healthy volunteers for six hours, and then CFU-GM was evaluated. Allogeneic CD3AK inhibited 20.44% CFU-GM formation, but autologous CD3AK had no inhibition on CFU-GM. It is concluded that CD3AK has no inhibition to autologous normal hematopoietic progenitor cells after cocultured with them from these results, while allogeneic CD3AK inhibits the normal hematopoietic progenitor cells significantly.